At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Rebecca Khan, MD, FACOG
Advertisement
Rebecca Khan, MD, FACOG, practiced obstetrics and gynecology for 21 years before serving as the director of women’s health for BioReference® Laboratories, LLC. Currently, Khan works in medical affairs at Thermo Fisher Scientific with a focus on placental biomarkers, sFlt-1 and PlGF.
Articles by Rebecca Khan, MD, FACOG
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Promises and Pitfalls of AI in Health Care
2
Texas Sues J&J, Kenvue for Alleged Deception in Acetaminophen Marketing
3
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
4
SCRI’s Vivek Subbiah, MD, Highlights Trials on Tumor-Agnostic Cancer Therapies During ESMO
5
